According to Fortune Business Insights, the North America drug delivery market size was valued at USD 702.04 billion in 2024 and is projected to grow from USD 743.20 billion in 2025 to USD 1,175.47 billion by 2032, exhibiting a CAGR of 6.8% during the forecast period. The market is experiencing strong growth due to the increasing prevalence of chronic diseases, rising demand for biologics and self-administered therapies, and continuous innovation in injectable, inhalation, transdermal, and oral drug delivery technologies.
Drug delivery systems play a critical role in modern healthcare by ensuring that therapeutic agents are delivered to the body in a safe, effective, and targeted manner. These systems are designed to improve treatment outcomes, enhance patient compliance, reduce dosing frequency, and optimize drug absorption. In North America, the market is expanding steadily as pharmaceutical and medical device companies focus on advanced delivery mechanisms for complex drugs, specialty therapeutics, and personalized treatment approaches.
One of the primary factors driving the growth of the North America drug delivery market is the increasing burden of chronic diseases such as diabetes, cancer, cardiovascular disorders, respiratory diseases, and autoimmune conditions. These conditions often require long-term medication management, frequent dosing, and precise administration, making efficient drug delivery systems essential for successful treatment outcomes.
The growing use of biologics, biosimilars, and specialty drugs is further accelerating demand for advanced drug delivery solutions. Biologic therapies often require injectable or infusion-based administration, which has led to increased adoption of prefilled syringes, autoinjectors, wearable injectors, and infusion delivery systems. As the pipeline for biologics continues to expand, pharmaceutical manufacturers are investing heavily in delivery technologies that can support product stability, accurate dosing, and patient convenience.
In addition, the region’s aging population is contributing to market growth, as older adults are more likely to require chronic disease management and long-term therapeutic support. This demographic trend is expected to increase demand for user-friendly, safe, and efficient drug delivery devices across both hospital and home-care settings.
The shift toward self-administration and home-based treatment is another major factor shaping the North America drug delivery market. Patients and healthcare providers are increasingly seeking treatment solutions that reduce hospital visits, lower healthcare costs, and improve convenience. This trend has encouraged the development of drug delivery devices that can be safely used by patients at home, including pen injectors, autoinjectors, inhalers, patch pumps, and connected drug delivery systems.
Self-administration is particularly important in the management of chronic and specialty conditions where regular dosing is required. Drug delivery devices designed for home use help improve treatment adherence and allow patients to manage therapy more independently. This has become especially relevant in therapeutic areas such as diabetes, rheumatoid arthritis, multiple sclerosis, fertility treatment, and hormone replacement therapy.
The expansion of home healthcare services and remote patient monitoring in the U.S. and Canada is also supporting market demand. Manufacturers are increasingly focusing on ergonomic device design, digital integration, safety features, and ease of use to address the growing need for patient-centric delivery solutions.
Technological innovation remains a key growth pillar for the North America drug delivery market. Companies are continuously developing advanced systems that improve precision, reduce drug wastage, and support targeted delivery. Injectable drug delivery remains one of the most significant segments in the market due to the growing use of biologics and the need for rapid therapeutic action in several disease categories.
In parallel, innovation in transdermal patches, inhalation devices, implantable delivery systems, nasal sprays, and controlled-release oral formulations is broadening the scope of drug delivery across therapeutic areas. Smart drug delivery systems integrated with connectivity features, dose tracking, and digital monitoring are also gaining traction, particularly as healthcare systems adopt more data-driven approaches to patient care.
Targeted drug delivery technologies are becoming increasingly important in oncology and specialty therapeutics, where the goal is to maximize efficacy while minimizing systemic side effects. Nanotechnology-based delivery platforms, liposomal formulations, and sustained-release systems are expected to contribute significantly to long-term market evolution.
The United States accounts for the largest share of the North America drug delivery market due to its strong pharmaceutical manufacturing base, advanced healthcare infrastructure, high biologics adoption, and significant spending on research and development. The country has a well-established ecosystem of pharmaceutical companies, medical device manufacturers, contract development organizations, and healthcare providers, all of which contribute to continuous innovation in drug delivery technologies.
The growing prevalence of chronic diseases, increasing demand for specialty medicines, and rising use of injectable therapies continue to support the U.S. market. In addition, regulatory approvals for advanced delivery devices and combination products are encouraging manufacturers to launch more patient-friendly and differentiated solutions.
Canada also represents an important market, supported by growing healthcare expenditure, rising awareness of chronic disease management, and increasing adoption of home-based treatment solutions. The country’s focus on improving access to modern therapies and healthcare services is expected to support steady market expansion over the forecast period.
The North America drug delivery market is highly competitive and includes pharmaceutical packaging specialists, medical device manufacturers, drug development service providers, and injectable system innovators. Companies are focusing on product innovation, strategic partnerships, capacity expansion, and acquisitions to strengthen their presence in high-growth segments such as injectable delivery, prefilled systems, and biologic-compatible packaging.